Medivation (MDVN) : Zacks Investment Research ranks Medivation (MDVN) as 5, which is a Strong Sell recommendation. 6 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. A total of 8 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 14 research analysts is 2.14, which indicates as a Buy.
Medivation (MDVN) : The highest short term price target forecast on Medivation (MDVN) is $82 and the lowest target price is $40. A total of 14 equity analysts are currently covering the company. The average price of all the analysts is $64.54 with a standard deviation of $10.85.
Shares of Medivation, Inc. rose by 23.08% in the last five trading days and 27.19% for the last 4 weeks. Medivation, Inc. is up 29.66% in the last 3-month period. Year-to-Date the stock performance stands at 66.05%. Medivation (NASDAQ:MDVN): On Tuesdays trading session , Opening price of the stock was $80.4 with an intraday high of $80.5. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $80.26. However, the stock managed to close at $80.27, a loss of 0.19% for the day. On the previous day, the stock had closed at $80.42. The total traded volume of the day was 16,752,884 shares.
Medivation, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company in collaboration with Astellas Pharma, Inc. has one commercial product, XTANDI (enzalutamide) capsules (XTANDI). XTANDI has received marketing approval in the United States, Europe, and other countries worldwide for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and in Japan for the treatment of patients with castration-resistant prostate cancer (CRPC). The Company in collaboration with Astellas is also conducting investigational studies of enzalutamide in prostate cancer and in advanced breast cancer. The Company has licensed exclusive worldwide rights to pidilizumab, an immune modulatory, anti-Programmed Death-1 (PD-1) monoclonal antibody for all potential indications from CureTech, Ltd.